These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 8539320)

  • 1. Opposite role of CCKA and CCKB receptors in the modulation of endogenous enkephalin antidepressant-like effects.
    Smadja C; Maldonado R; Turcaud S; Fournie-Zaluski MC; Roques BP
    Psychopharmacology (Berl); 1995 Aug; 120(4):400-8. PubMed ID: 8539320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCKA, but not CCKB, agonists suppress the hyperlocomotion induced by endogenous enkephalins, protected from enzymatic degradation by systemic RB 101.
    Dauge V; Corringer PJ; Roques BP
    Pharmacol Biochem Behav; 1995 Feb; 50(2):133-9. PubMed ID: 7740050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antidepressant-like effects of CCKB antagonists in mice: antagonism by naltrindole.
    Derrien M; Durieux C; Roques BP
    Br J Pharmacol; 1994 Mar; 111(3):956-60. PubMed ID: 8019773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCK-B receptors in the limbic system modulate the antidepressant-like effects induced by endogenous enkephalins.
    Smadja C; Ruiz F; Coric P; Fournié-Zaluski MC; Roques BP; Maldonado R
    Psychopharmacology (Berl); 1997 Aug; 132(3):227-36. PubMed ID: 9292622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidepressant-like effects of CCK(B) receptor antagonists: involvement of the opioid system.
    Hernando F; Fuentes JA; Fournié-Zaluski MC; Roques BP; Ruiz-Gayo M
    Eur J Pharmacol; 1996 Dec; 318(2-3):221-9. PubMed ID: 9016909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of endogenous cholecystokinin in the facilitation of mu-mediated antinociception by delta-opioid agonists.
    Noble F; Smadja C; Roques BP
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1127-34. PubMed ID: 7996417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of opioid antinociception by CCK at the supraspinal level: evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain.
    Noble F; Derrien M; Roques BP
    Br J Pharmacol; 1993 Aug; 109(4):1064-70. PubMed ID: 8401918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CCKB receptor antagonist, L-365,260, elicits antidepressant-type effects in the forced-swim test in mice.
    Hernando F; Fuentes JA; Roques BP; Ruiz-Gayo M
    Eur J Pharmacol; 1994 Aug; 261(3):257-63. PubMed ID: 7813546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulation of delta-opioid receptors reduces the in vivo binding of the cholecystokinin (CCK)-B-selective agonist [3H]pBC 264: evidence for a physiological regulation of CCKergic systems by endogenous enkephalins.
    Ruiz-Gayo M; Durieux C; Fournié-Zaluski MC; Roques BP
    J Neurochem; 1992 Nov; 59(5):1805-11. PubMed ID: 1357099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins.
    Valverde O; Maldonado R; Fournie-Zaluski MC; Roques BP
    J Pharmacol Exp Ther; 1994 Jul; 270(1):77-88. PubMed ID: 8035345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid delta and dopamine D1 receptor stimulation.
    Baamonde A; Daugé V; Ruiz-Gayo M; Fulga IG; Turcaud S; Fournié-Zaluski MC; Roques BP
    Eur J Pharmacol; 1992 Jun; 216(2):157-66. PubMed ID: 1327810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of morphine withdrawal by the association of RB 101, an inhibitor of enkephalin catabolism, and the CCKB antagonist PD-134,308.
    Maldonado R; Valverde O; Ducos B; Blommaert AG; Fournie-Zaluski MC; Roques BP
    Br J Pharmacol; 1995 Mar; 114(5):1031-9. PubMed ID: 7780637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weak tolerance to the antinociceptive effect induced by the association of a peptidase inhibitor and a CCKB receptor antagonist.
    Valverde O; Blommaert AG; Fournié-Zaluski MC; Roques BP; Maldonado R
    Eur J Pharmacol; 1995 Nov; 286(1):79-93. PubMed ID: 8566154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A selective CCKB receptor antagonist potentiates, mu-, but not delta-opioid receptor-mediated antinociception in the formalin test.
    Noble F; Blommaert A; Fournié-Zaluski MC; Roques BP
    Eur J Pharmacol; 1995 Jan; 273(1-2):145-51. PubMed ID: 7737308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo occupation of mouse brain opioid receptors by endogenous enkephalins: blockade of enkephalin degrading enzymes by RB 101 inhibits [3H]diprenorphine binding.
    Ruiz-Gayo M; Baamonde A; Turcaud S; Fournie-Zaluski MC; Roques BP
    Brain Res; 1992 Feb; 571(2):306-12. PubMed ID: 1319268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opposite role of delta 1- and delta 2-opioid receptors activated by endogenous or exogenous opioid agonists on the endogenous cholecystokinin system: further evidence for delta-opioid receptor heterogeneity.
    Noble F; Fournie-Zaluski MC; Roques BP
    Neuroscience; 1996 Dec; 75(3):917-26. PubMed ID: 8951884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of the peptidase inhibitor RB 101 and a CCK-B antagonist strongly enhances antinociceptive responses.
    Maldonado R; Derrien M; Noble F; Roques BP
    Neuroreport; 1993 Jul; 4(7):947-50. PubMed ID: 8369487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholecystokinin-A but not cholecystokinin-B receptor stimulation induces endogenous opioid-dependent antinociceptive effects in the hot plate test in mice.
    Derrien M; Noble F; Maldonado R; Roques BP
    Neurosci Lett; 1993 Oct; 160(2):193-6. PubMed ID: 8247353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of receptor desensitization to analyse CCKA and CCKB/gastrin receptors coupled to contraction in guinea-pig stomach muscle.
    Bishop LA; Gerskowitch VP; Hull RA; Shankley NP; Black JW
    Br J Pharmacol; 1995 Jan; 114(2):339-48. PubMed ID: 7881733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCKA receptor antagonist devazepide but not by the CCKB receptor antagonist L-365,260.
    O'Neill MF; Dourish CT; Iversen SD
    Eur J Pharmacol; 1991 Feb; 193(2):203-8. PubMed ID: 2050197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.